A Double-Blind Randomized Controlled Trial To Study the Efficacy of Topiramate in a Civilian Sample of PTSD
| Autor: | Sergio Baxter Andreoli, Jair de Jesus Mari, Mary S. L. Yeh, Mariana Caddrobi Pupo Costa, Marcelo Feijó de Mello, Rodrigo A. Bressan |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Pharmacology
Topiramate medicine.medical_specialty Clinician Administered PTSD Scale Beck Depression Inventory Placebo law.invention Psychiatry and Mental health Tolerability Randomized controlled trial law Physiology (medical) Internal medicine Clinical Global Impression medicine Outpatient clinic Pharmacology (medical) Psychology Psychiatry medicine.drug |
| Zdroj: | CNS Neuroscience & Therapeutics. 17:305-310 |
| ISSN: | 1755-5930 |
| DOI: | 10.1111/j.1755-5949.2010.00188.x |
| Popis: | SUMMARY Objective: To evaluate the efficacy and tolerability of topiramate in patients with posttraumatic stress disorder (PTSD). Method: We conducted a 12-week double-blind, randomized, placebo-controlled study comparing topiramate to placebo. Men and women aged 18–62 years with diagnosis of PTSD according to DSM-IV were recruited from the outpatient clinic of the violence program of Federal University of Sao Paulo Hospital (Prove-UNIFESP), Sao Paulo City, between April 2006 and December 2009. Subjects were assessed for the Clinician-Administered Posttraumatic Stress Scale (CAPS), Clinical Global Impression, and Beck Depression Inventory (BDI). After 1-week period of washout, 35 patients were randomized to either group. The primary outcome measure was the CAPS total score changes from baseline to the endpoint. Results: 82.35% of patients in the topiramate group exhibited improvements in PTSD symptoms. The efficacy analysis demonstrated that patients in the topiramate group exhibited significant improvements in reexperiencing symptoms: flashbacks, intrusive memories, and nightmares of the trauma (CAPS-B; P= 0.04) and in avoidance/numbing symptoms associated with the trauma, social isolation, and emotional numbing (CAPS-C; P= 0.0001). Furthermore, the experimental group demonstrated a significant difference in decrease in CAPS total score (topiramate −57.78; placebo −32.41; P= 0.0076). Mean topiramate dose was 102.94 mg/d. Topiramate was generally well tolerated. Conclusion: Topiramate was effective in improving reexperiencing and avoidance/numbing symptom clusters in patients with PTSD. This study supports the use of anticonvulsants for the improvement of symptoms of PTSD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text